Efficacy and safety of inhaled ciclesonide compared with chlorofluorocarbon beclomethasone dipropionate in adults with moderate to severe persistent asthma

Respirology

Volumn 12, Issue 4, 2007, Pages 573-580

  Adachi, Mitsuru ^a,j   Ishihara, Kyosuke ^b   Inoue, Hiroshi ^c   Kudo, Koichiro ^d   Takahashi, Kiyoshi ^e   Morita, Yutaka ^f   Masuda, Ken Ichi ^g   Sakai, Tomoki ^g   Kato, Ryuichi ^h   Miyamoto, Terumasa ⁱ  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e Minami Okayama Medical Center   (Japan)

^f OCHANOMIZU UNIVERSITY   (Japan)

^g TEIJIN PHARMA LIMITED   (Japan)

^h KEIO UNIVERSITY   (Japan)

ⁱ Clinical Research Institute   (Japan)

^j SHOWA UNIVERSITY   (Japan)

more..

Author keywords

Ciclesonide; Inhaled corticosteroid; Moderate to severe asthma; On site activation; Safety

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; CICLESONIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; MIDDLE AGED; PREGNENEDIONES;

EID: 34250728522     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2007.01112.x     Document Type: Article

References (31)

1. Makino S, Furusho K, Miyamoto T, Ohta K (eds). Pharmacologic control of asthma. Asthma prevention and management guidelines. 1998, Japan (JGL 1998): English version. Int. Arch. Allergy Immunol. 2000 121 (Suppl. 1 37 70.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: HHLB/WHO, workshop report. Updated 2005. [Accessed 7 September 2006.] Available from URL: http://www.ginasthma.com
3. National Institutes of Health. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. 1997. NIH Publication No. 97-4051.
4. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000 16 : 802 7.
5. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J. Allergy Clin. Immunol. 2004 114 : 40 7.
6. Adachi M, Morikawa A, Ishihara K. Asthma insights and reality in Japan (AIRJ). Arerugi. (Jpn. J. Allergol.) 2002 51 : 411 20 (Abstract in English).
7. Wilson AM, Clark DJ, McFarlane L, Lipworth BJ. Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers. Eur. J. Clin. Pharmacol. 1997 53 : 33 7.
8. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996 51 : 262 6.
9. Marystone JF, Barrett-Connor EL, Morton DJ. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J. Allergy Clin. Immunol. 1995 96 : 571 9.
10. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N. Engl. J. Med. 2001 345 : 941 7.
11. Fukushima C, Matsuse H, Tomari S, Obase Y, Miyazaki Y et al. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann. Allergy Asthma Immunol. 2003 90 : 646 51.
12. Toogood JH, Jennings B, Greenway RW, Chuang L. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J. Allergy Clin. Immunol. 1980 65 : 145 53.
13. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur. Respir. J. 1995 8 : 590 2.
14. Dietzel K, Engelstätter R, Keller A. Ciclesonide: an on-site-activated steroid. Prog. Respir. Res. 2001 31 : 91 3.
15. Stoeck M, Riedel R, Hochhaus G, Häfner D, Masso JM et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J. Pharmacol. Exp. Ther. 2004 309 : 249 58.
16. Nave R, Hummel R-P, Wohlsen A, Herzog R, Zech K. The active metabolite of ciclesonide, des-isobutyryl ciclesonide, forms highly lipophilic fatty acid conjugates in precision-cut rat lung slices. Am. J. Respir. Crit. Care Med. 2004 169 : A91.
17. Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm. Pharmacol. Ther 2005 18 : 390 6.
18. Nave R, Bethke TD, Marle SP, Zech K. Pharmacokinetics of [14C] Ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokinet. 2004 43 : 479 86.
19. Rohatagi S, Luo Y, Shen L, Guo Z, Schemm C et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, Ciclesonide. Am. J. Ther. 2005 12 : 201 9.
20. Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm. Drug Dispost. 2006 27 : 197 207.
21. Leach CL, Bethke TD, Boudreau RJ, Hasselquist BE, Drollmann A et al. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J. Aerosol. Med. 2006 19 : 117 26.
22. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of (99m) Tc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir. Med. 2005 100 : 375 84.
23. Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J. Clin. Pharmacol. 2005 45 : 146 52.
24. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled cidesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur. J. Clin. Pharmacol. 2005 61 : 203 8.
25. Tsukioka K, ed. Peak Expiratory Flow in Normal, Healthy Japanese Subjects. Kyowa Kikaku, Tokyo, 1995.
26. Miyamoto T, Shida T, Tomioka T, Makino S, Kabe J et al. Report of the expert committee for reviewing the criteria for severity of bronchial asthma. Jpn. J. Allergol. 1994 43 : 71 80 (in Japanese).
27. Gross G, Thompson PJ, Chervinsky P, Burgt JV. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma. Chest 1999 155 : 343 51.
28. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL et al. Inhaled corticosteroids: past lessons and future issues. J. Allergy. Clin. Immunol. 2003 112 (3 Suppl. S1 40.
29. Derom E, Van De Velde V, Marissens S, Engelstätter R, Vincken W et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm. Pharmacol. Ther. 2005 18 : 328 36.
30. Hansel TT, Benezet O, Kafe H, Ponitz HH, Cheung D et al. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin. Ther. 2006 28 : 906 20.
31. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006 61 : 518 26.